Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC, brings light upon the tendency of the healthcare community to favour an immediate diagnosis for patients with acute myeloid leukemia (AML), despite this doing more harm than good to patients. Waiting for genetic results can be a lengthy process, yet Dr Erba presents a compelling argument using evidence from a recent trial held in France in which patients with FLT3 mutations in AML showed increased chance of survival when taking targeted therapy. Dr Erba highlights the benefits of gene targeted therapy in AML; supporting the need to stratify patients to different treatments.
Gene-based treatments show positive outcomes in AML
